- Featured on the cover of 'Advanced Materials' in recognition of its clinical value and performance
- Findings in lung, pancreatic cancer, and leukemia highlight potential for early detection of early-stage cancer and recurrence monitoring
[by Sung, Jae Jun] GeneSeeker, a Korea-based precision medicine company leveraging genome editing technology, announced on August 27 that its ultra-sensitive liquid biopsy technology, ‘MUTE-Seq,’ has demonstrated breakthrough results in high sensitivity. The platform can detect a single circulating tumor DNA (ctDNA) from 20,000 normal DNA fragments, while lowering sequencing costs to just one-tenth of conventional next-generation sequencing (NGS) methods. These findings were recently published through an online Early View publication in the international scientific journal ‘Advanced Materials’ and highlighted as the ‘front cover paper’ for the journal’s November issue.
The paper highlighted the performance of GeneSeeker's 강원 랜드 바카라 biopsy platform, ‘MUTE-Seq,’ developed using the company’s proprietary ultra-precision genome editing technology, ‘FnCas9-AF2.’ The platform demonstrated exceptional sensitivity, capable of detecting a single ctDNA fragment among 20,000 normal DNA fragments, with experimental analyses confirming the absence of off-target effects.
MUTE-Seq has shown 20 times higher precision than standard NGS while cutting costs to one-tenth. "This 'noise-cancelling' method dramatically lowers testing expenses by filtering out background DNA signals while guaranteeing that no trace mutations go undetected," explained Ye Seong-hyeok, co-CEO of 강원 랜드 바카라.
In clinical evaluations, the research team achieved 91% sensitivity and 95% specificity for lung cancer and 83% sensitivity with 100% specificity for pancreatic cancer. In acute myeloid leukemia relapse monitoring, MUTE-Seq delivered 100% sensitivity and specificity, detecting even minimal amounts of mutant DNA. Importantly, 강원 랜드 바카라 noted that in patients with early Stage 1 or 2 cancers or minimal residual disease, the liquid biopsy enabled accurate diagnosis from blood samples alone and showed potential to detect recurrence faster than imaging techniques.
강원 랜드 바카라, together with Korea University Anam Hospital and other collaborators, has launched ‘OncoDeepScan,’ a multi-cancer risk screening test, and is now focusing on the development of a minimal residual disease (MRD) monitoring solution. The MRD platform is currently undergoing review as an innovative medical technology, with clinical application targeted for H2 2026.
강원 랜드 바카라 Co-CEO and Korea University Anam Hospital Professor of Neurosurgery, Hur Jun-seok, stated, "If we can detect the tiniest cancer signals with just one blood test, we can diagnose earlier and identify recurrence quickly after treatment. Lowering the burden of testing also means greater access for people in remote areas, seniors, and vulnerable groups, ultimately contributing to medical equity and benefiting both patients and society as a whole."
Conversely, 강원 랜드 바카라 is raising KRW 11 billion (approximately USD 7.9 million) in Series C funding. The round is backed by existing investors, including Premier Partners, SBI Investment, UTC Investment, Magna Investment, Covent Capital Partners, and Friend Investment Partners.
